CN115844821A - Desonide nanocrystal suspension, preparation method and application thereof - Google Patents
Desonide nanocrystal suspension, preparation method and application thereof Download PDFInfo
- Publication number
- CN115844821A CN115844821A CN202310004044.0A CN202310004044A CN115844821A CN 115844821 A CN115844821 A CN 115844821A CN 202310004044 A CN202310004044 A CN 202310004044A CN 115844821 A CN115844821 A CN 115844821A
- Authority
- CN
- China
- Prior art keywords
- donepezil
- nanocrystal
- desonide
- suspension
- carbomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960003662 desonide Drugs 0.000 title claims abstract description 87
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 title claims abstract description 87
- 239000002159 nanocrystal Substances 0.000 title claims abstract description 63
- 239000000725 suspension Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims abstract description 114
- 229960003530 donepezil Drugs 0.000 claims abstract description 57
- 239000002245 particle Substances 0.000 claims abstract description 17
- 239000000243 solution Substances 0.000 claims abstract description 16
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 11
- 239000003381 stabilizer Substances 0.000 claims abstract description 8
- 239000006071 cream Substances 0.000 claims description 23
- 238000000227 grinding Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical group O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000499 gel Substances 0.000 claims description 18
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 16
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 16
- 239000006210 lotion Substances 0.000 claims description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- 229960001631 carbomer Drugs 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 8
- 238000009826 distribution Methods 0.000 claims description 5
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 238000000149 argon plasma sintering Methods 0.000 claims description 3
- 229940049638 carbomer homopolymer type c Drugs 0.000 claims description 3
- 229940043234 carbomer-940 Drugs 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000003871 white petrolatum Substances 0.000 claims description 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 229940075509 carbomer 1342 Drugs 0.000 claims description 2
- 229940082484 carbomer-934 Drugs 0.000 claims description 2
- 229940085237 carbomer-980 Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000007765 cera alba Substances 0.000 claims description 2
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000003801 milling Methods 0.000 claims description 2
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 claims description 2
- 229940055577 oleyl alcohol Drugs 0.000 claims description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 abstract description 42
- 229940079593 drug Drugs 0.000 abstract description 23
- 230000007547 defect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 4
- 229960004436 budesonide Drugs 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 229940125379 topical corticosteroid Drugs 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007709 nanocrystallization Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Images
Abstract
The invention relates to the technical field of medicines, and provides a donepezil nanocrystal suspension, a preparation method and application thereof. The donepezil nanocrystal suspension comprises a stabilizer solution and a donepezil nanocrystal; the particle size range of the donepezil nanocrystal is 100-1000nm, and the potential is-10 mv to-50 mv; the stabilizer solution is an aqueous solution of Sodium Dodecyl Sulfate (SDS), and the mass fraction (g/g) of the sodium dodecyl sulfate is 10-20%. The invention overcomes the defects of the prior art and solves the technical problems of low solubility of the desonide and low skin permeation amount in the prior external preparation.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a donepezil nanocrystal suspension, a preparation method and application thereof.
Background
Desonide is a synthetic, low-potency, non-fluorinated topical corticosteroid effective in a wide variety of dermatological conditions for which corticosteroid therapy is effective, and has been widely used for many years for the topical treatment of mild to moderate atopic dermatitis (eczema, psoriasis, contact dermatitis, neurodermatitis, seborrheic dermatitis, etc. resulting in skin inflammation and redness, swelling, itching, discomfort, etc. of the skin). Multiple clinical trial studies have confirmed the safety and efficacy of this drug, and desonide has a critical position as a topical corticosteroid hormone.
However, the solubility of the desonide is poor due to the chemical structure of the desonide, after the desonide is prepared into an external preparation, such as cream, gel, ointment and lotion, the desonide is suspended in a system, and due to the characteristic of poor solubility, the release speed of the desonide is slow, so that the desonide cannot be rapidly released to permeate through the stratum corneum in a short time, the skin permeation amount of the desonide is low, the effect is slow, and the disease can be effectively treated by using the desonide for many times, for example, the external use of the desonide lotion needs to be carried out 2-4 times a day clinically. However, because the donepezil is a glucocorticoid drug, multiple side effects, such as fungal infection, epidermal atrophy and the like, can be caused by long-term use of the donepezil for a high frequency, and even the risk of systemic adverse reaction is caused. Therefore, the physical and chemical properties of the desonide are improved, the transdermal permeation quantity of the desonide is improved, the local curative effect of the medicine is increased, and the clinical advantage of the product can be obviously improved by shortening the use frequency of the medicine.
The external preparation of desonide is administered transdermally, and its permeation route is the epidermal route, whereas for trans-membrane transport of the epidermal route, it occurs on the premise that the pharmaceutically active ingredient (API) is present in the form of a molecule (dissolved state). Therefore, the solubility of the desonide is improved, and the active effects of improving the transdermal permeation quantity of the desonide, increasing the local curative effect of the medicine and shortening the use frequency of the medicine are achieved.
The nanocrystalline technology is a novel pharmaceutical technology for increasing the solubility of insoluble drugs. It is currently believed that the mechanism of action of nanocrystals includes: 1. the release speed of the medicine is improved: according to the famous pharmacy Noyes-Whitney equation dC/dt = kD A (Cs-Ct) (wherein dC/dt is dissolution rate, kD is dissolution rate constant, A is specific surface area, cs is drug saturation solubility, and Ct is drug concentration), the dissolution rate of the drug is in positive correlation with the specific surface area of the drug. The nanocrystalline increases the specific surface area of the medicine by nanocrystallization, and improves the dissolution rate of the insoluble medicine. Data show that under the same dissolution condition, when the particle size of cilostazol is reduced from 13 μm to 220nm, the dissolution speed of the drug is increased to 5100 times of the original speed; 2. improving the solubility of the drug: according to another well-known pharmaceutical Ostwald-Freundlich equation (lgS 2/S1=2M σ (1/R2-1/R1)/ρ RT) (where S2 and S1 are solubilities of drugs at different sizes, R2 and R1 are sizes of drugs, M denotes a relative molecular mass of drugs, σ is an interfacial tension between solid and liquid, ρ is a density of drugs, R is a molar gas constant, and T is a thermodynamic temperature), the greater the difference in solubility is, the greater the difference in particle size is. After the medicine is prepared into the nano-crystal, the size of the medicine is greatly reduced, so that the solubility of the medicine in a system is directly improved, and the slightly soluble medicine is more easily dissolved in the system.
Therefore, a donepezil nanocrystal suspension, a preparation method and application thereof are provided.
Disclosure of Invention
Technical problem to be solved
Aiming at the defects of the prior art, the invention provides a donepezil nanocrystal suspension, a preparation method and application thereof, and solves the technical problems of low solubility of the donepezil and low skin permeation in the prior external preparation.
(II) technical scheme
In order to achieve the purpose, the invention is realized by the following technical scheme:
a donepezil nanocrystal suspension is characterized in that:
the suspension comprises a stabilizer solution and a donepezil nanocrystal suspended in the stabilizer solution;
the particle size range of the donepezil nanocrystal is 100-1000nm, and the potential is-10 mv to-50 mv;
the stabilizer solution is an aqueous solution of Sodium Dodecyl Sulfate (SDS), and the mass fraction (g/g) of the sodium dodecyl sulfate is 10-20%.
Furthermore, the light scattering average particle size of the desonide nanocrystal is 354.7nm, the PDI of the particle size distribution is 0.204, and the average potential is-26.9 mv.
A preparation method of a donepezil nanocrystal suspension is characterized by comprising the following steps: the method comprises the following steps of mixing aqueous solution of the desonide and the sodium dodecyl sulfate according to a ratio of 1:20 (g/ml) and grinding, and obtaining suspension, namely the suspension of the desonide nanocrystal after grinding.
Further, the budesonide is pre-pulverized to a particle size D90 of 5 to 10 μm before being pulverized.
Furthermore, the grinding adopts a medium grinding method, the grinding equipment is a ball mill, and the grinding medium is zirconia beads.
Further, the particle size of the zirconia beads is 0.4mm, and the ratio of the zirconia beads to the aqueous solution of sodium dodecyl sulfate is 1:5 (g/ml), and the milling parameters were 2000rpm,12h.
The invention also provides application of the donepezil nanocrystal suspension in a donepezil external preparation.
Further, the external preparation comprises cream, gel, ointment, lotion.
Furthermore, the cream is prepared from a donepezil nanocrystal suspension, an oil phase, a water phase and a surfactant;
the oily matrix of the oil phase is one or more selected from light liquid paraffin, cetostearyl alcohol, white vaseline and beeswax;
the surfactant is a polyoxyethylene ether emulsifier, and the polyoxyethylene ether emulsifier is selected from one or more of castor oil polyoxyethylene ether, nonylphenol polyoxyethylene ether, octylphenol polyoxyethylene ether, oleyl alcohol polyoxyethylene ether, fatty alcohol polyoxyethylene ether and methyl stearate polyoxyethylene ether.
Furthermore, the gel is prepared from a donepezil nanocrystal suspension, a thickening agent, a cellulose derivative, chitosan, polyvinylpyrrolidone and polyvinyl alcohol;
the thickening agent is carbomer, and the carbomer is selected from one or more of carbomer 940, carbomer 941, carbomer 934, carbomer 1342, carbomer 980, carbomer ETD 2020, carbomer SF-1 and carbomer Ultrez;
the cellulose derivative is selected from one or more of hydroxypropyl cellulose, hydroxypropyl methylcellulose and carboxymethyl cellulose.
(III) advantageous effects
The scheme provided by the invention has the following beneficial effects:
1. according to the invention, on the premise of not changing the molecular structure of the drug, the physical and chemical properties of the desonide are improved by pretreating the desonide, and the solubility and dissolution speed of the drug are increased, so that the transdermal rate and transdermal absorption amount of the desonide when being externally used are further improved, the curative effect of the drug is enhanced, the use frequency of the drug is reduced, the effectiveness and safety of the drug are improved, the basic theory of the drug economy is met, and the clinical value of the product is improved.
2. The prepared donepezil nanocrystal suspension has good stability and is not easy to generate obvious aggregation; the external reagent prepared by the donepezil nanocrystal suspension is also the same, so that the donepezil nanocrystals in the reagent do not obviously aggregate within at least one month, and the stability and the effectiveness are controllable.
3. The method adopts a medium grinding method to obtain the donepezil nanocrystal suspension, belongs to a common crushing mode in domestic industry, has no special requirements on equipment compared with methods such as a high-pressure homogenization method, a precipitation method, a solvent evaporation method, a spray drying method and the like introduced abroad, and is easier to popularize and apply in process.
Drawings
FIG. 1 is a graph showing the distribution of the diameter of the nano-sized particles of the donepezil prepared in example 1;
FIG. 2 is a graph showing the potential distribution of the nano-crystals of desonide prepared in example 1;
FIG. 3 is an electron microscope scanning image of the nano-crystalline desonide prepared in example 1, wherein the scale on the left is 1 μm and the scale on the right is 200nm;
figure 4 is an electron micrograph of the nano-sized suspension of budesonide of control 1 in example 1 taken 12h after preparation.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are a part of the embodiments of the present invention, but not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1: preparation and transdermal absorption of desonide nanocrystalline cream
(1) Preparation of nano-crystalline of desonide
In this example, a dielectric grinding method is used to prepare the nano-crystalline of the desonide. Firstly, grinding a desonide raw material drug to a particle size D90 of about 5-10 mu m by using an airflow grinder, weighing 5g of the ground desonide raw material drug, adding the 5g of the ground desonide raw material drug into 100ml of aqueous solution of sodium dodecyl sulfate, uniformly dispersing the mixture by using a high-shear emulsifying machine (the shear speed is 10000 rpm) for 10min, transferring the mixture into a medium grinding machine, adding 20g of zirconia beads with the diameter of 0.4mm serving as grinding media, grinding the mixture at 2000rpm for 12h, and separating the zirconia beads to obtain a desonide nanocrystal suspension. The grain size and potential of the prepared nanocrystals, and scanning electron microscopy are shown in fig. 1, fig. 2, and fig. 3, respectively. The results show that the nano-crystalline of the desonide prepared by the embodiment is columnar crystal, the grain diameter ranges from 100 nm to 500nm, the light scattering average grain diameter is 354.7nm, the PDI of the grain diameter distribution is 0.204, the electric potential ranges from-10 mv to 50mv, and the average electric potential is-26.9 mv.
The mass fractions (g/g) of the aqueous solution of sodium dodecyl sulfate in the above preparation methods were adjusted to 5%, 10%, 15%, and 25%, to obtain four sets of donepezil nanocrystal suspension controls, control 1, control 2, control 3, and control 4, respectively. In contrast 4, the mass fraction of sodium dodecyl sulfate is 25%, the medium foams seriously, and the lubrication effect is large, which affects the impact force and the collision strength of zirconia beads in the grinding machine, so that the donepezil nanocrystals meeting the particle size requirement (100-1000 nm) cannot be prepared, and the subsequent observation of the donepezil nanocrystal suspension is not performed. In the present example and the first three groups of controls, nano-scale suspension of the desonide nanocrystals can be prepared, and scanning is performed every hour to observe the condition of the desonide nanocrystals in the suspension, in contrast 1, see fig. 4, at room temperature, in 12 hours, a significant aggregation phenomenon occurs, and in contrast 2, 3 and in example 12 hours, a significant aggregation phenomenon occurs, wherein 40-50 μm particles of the desonide are observed.
(2) Preparation of Desonide nanocrystalline cream
Weighing the raw and auxiliary materials according to the prescription in the table for later use. Heating white vaseline, liquid paraffin, cetostearyl alcohol, tween 80 and span 60 to 70-80 ℃ for dissolving to obtain an oil phase for later use; heating purified water, propylene glycol and methyl paraben to 70-80 ℃ for later use. Then mixing the oil phase and the water phase, and mixing for 30min at 80 ℃ to obtain an intermediate. And then cooling the intermediate by using cooling water. When the temperature of the paste body is reduced to 60 ℃, the nano-crystalline of the desonide is added, and the paste body is cut at 2000rpm for 30min and then is continuously cooled to obtain a finished product. And according to the same prescription process, the same specification of the desonide cream is prepared by using the desonide with the grain diameter of micron grade (D90 is between 5 and 10 mu m).
(3) Transdermal absorption of the Desonide nanocrystal cream
Comparing the nano-crystalline cream of desonide prepared in (2)' with common nano-crystalline cream of desonide by transdermal absorption, and adopting the area of the medicine applied to the cream of 1.77cm 2 Franz diffusion cell with 8mL receiving cell volume, and Bama miniature pig skin as permeation barrier (one month old) at 10mg/cm 2 And (3) applying the medicine, wherein the medicine applying amount is about 17.7mg, the receiving solution is normal saline, and an in-vitro transdermal test is carried out, wherein the temperature is set to be 32 ℃, the rotating speed is 600rpm, n =6, and the sampling time points are 4, 8, 12 and 24 hours. The results obtained are shown in the following table. From the results of tables 1 and 2, it is understood that the transdermal permeation amount and the skin retention amount (p < 0.05) of the donepezil are significantly improved when the donepezil is prepared into the nanocrystal, as compared to the micron-sized donepezil.
TABLE 1 cumulative transdermal amounts of Desonide nanocrystalline cream and Desonide cream
TABLE 2 skin Retention of Desonide nanocrystalline cream and Desonide cream
(4) Storage of a Desonide nanocrystalline cream
The storage conditions were: at room temperature (30 deg.C), in the shade.
Sampling every 24h to observe the transformation condition of the nano-crystalline of the desonide in the cream, and no obvious aggregation occurs within 30 days.
In addition, when the donepezil nanocrystal cream prepared from the donepezil nanocrystal suspension obtained in control 1 was used, it was found that aggregation occurred in a short time after the cream was prepared.
Example 2: preparation and transdermal absorption of desonide nanocrystalline gel
(1) Preparation of the Desonide nanocrystal
Preparation of the nano-crystalline forms of the desonide is referred to the preparation method of the nano-crystalline forms of the desonide in "example 1". The preparation process is the same as that in "example 1", and the nano-crystalline of the desonide is prepared by a medium grinding method.
(2) Preparation of desonide nanocrystalline gel
Weighing the raw and auxiliary materials according to the prescription in the table for later use. 10g of purified water was added to the sodium hydroxide to dissolve the sodium hydroxide to prepare an aqueous solution of sodium hydroxide. Adding the prescribed amount of water into a container, adding ethyl p-hydroxybenzoate, heating, stirring to dissolve, cooling, adding carbomer 940, and standing overnight to allow it to swell sufficiently. And adding the propylene glycol according to the prescription amount, stirring uniformly, then adding the donepezil nanocrystal or the donepezil, continuing stirring uniformly, then adding the aqueous solution of the sodium hydroxide, and stirring uniformly to obtain the donepezil nanocrystal gel and the donepezil gel.
(3) Transdermal absorption of a gel of nano crystals of desonide
Comparing the nano-crystalline gel of the desonide prepared in the step (2) with the common gel of the desonide in a percutaneous absorption way, and adopting the medicine application area of 1.77cm 2 Franz diffusion cell with 8mL receiving cell volume, and Bama miniature pig skin as permeation barrier (one month old) at 10mg/cm 2 And (3) applying the medicine, wherein the medicine applying amount is about 17.7mg, the receiving solution is normal saline, and an in-vitro transdermal test is carried out, wherein the temperature is set to be 32 ℃, the rotating speed is 600rpm, n =6, and the sampling time points are 4, 8, 12 and 24 hours. The results obtained are shown in the following table. The results show that nano-crystalline desonide can also significantly increase the transdermal penetration and skin retention (p < 0.05) of desonide when the dosage form of desonide is changed to gel, which is consistent with the results of the cream of "example 1".
TABLE 3 cumulative transdermal amounts of desonide nanocrystal gels and desonide gels
TABLE 4 Denide nanocrystalline gels and skin retentions of the Denide gels
(4) Storage of desonide nanocrystalline gels
The storage conditions were: no more than 20 deg.C, and shade.
Sampling every 24h to observe the transformation condition of the nano-crystalline of the desonide in the cream, and no obvious aggregation occurs within 30 days.
Example 3: preparation and transdermal absorption of desonide nanocrystalline lotion
(1) Preparation of the Desonide nanocrystal
Preparation of the nano-crystalline forms of the desonide is referred to the preparation method of the nano-crystalline forms of the desonide in "example 1". The preparation process is the same as that in "example 1", and the nano-crystalline of the donepezil is prepared by a medium grinding method.
(2) Preparation of nano-crystalline detergent of desonide
Weighing the raw and auxiliary materials according to the prescription in the table for later use. Preparation of an aqueous phase: weighing purified water with a general prescription amount at 80 ℃, adding hydroxypropyl methylcellulose, stirring and dispersing, adding purified water with a general prescription amount, and stirring and dissolving; then adding glycerol, disodium ethylene diamine tetraacetate, phenoxyethanol, citric acid and sodium citrate, heating at 80 ℃, stirring and dissolving completely, preserving heat, adding the nano-crystalline of the budesonide or the budesonide, stirring and dispersing uniformly; preparation of oil phase: weighing span 8, liquid paraffin and cetostearyl alcohol according to the prescription amount, heating and melting completely at 80 ℃, and preserving heat; emulsification: and (3) adding the water phase into the oil phase at the temperature of 80 ℃, stirring and emulsifying for 10min at 40rpm, and gradually cooling to room temperature to obtain the donepezil nanocrystal/donepezil lotion.
(3) Transdermal absorption of donepezil nanocrystalline lotion
Comparing the nano-crystalline lotion of the desonide prepared in the step (2) with the common lotion of the desonide in a percutaneous absorption way, and adopting the application area of 1.77cm 2 Franz diffusion cell with 8mL receiving cell volume, and Bama miniature pig skin as permeation barrier (one month old) at 10mg/cm 2 Applying the medicine, wherein the medicine applying amount is about 17.7mg, and the receiving liquid is physiological saline to carry out an in-vitro transdermal test, wherein the temperature is set to be 32 ℃, the rotating speed is 600rpm, n =6, and the sampling time points are 4, 8, 12 and 24h. The results obtained are shown in the following table. The result shows that after the dosage form of the desonide is changed into the lotion, the nano-crystallized desonide can also obviously improve the transdermal permeation quantity and the skin retention quantity (p is less than 0.05) of the desonide, and in addition, the transdermal result of the lotion shows that the transdermal cumulative permeation quantity and the skin retention quantity of the desonide are obviously higher than those of the cream and the gel after the desonide is prepared into the lotion. This is probably due to the low viscosity of the lotion, and the faster dissolution and transport of the desonide through the membrane in the system.
TABLE 5 cumulative transdermal amounts of DENEDEAD NANOCRYSTAL WASHING AGENT AND DENEDENDAD WASHING AGENT
TABLE 6 skin Retention of Desonide nanocrystal lotions and Desonide lotions
(4) Storage of a Desonide nanocrystal wash solution
The storage conditions were: at room temperature (30 deg.C), in the shade.
Sampling every 24h to observe the transformation condition of the desonide nanocrystals in the washing liquid, and no obvious aggregation occurs within 30 days.
It should be noted that, in this document, the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (10)
1. A donepezil nanocrystal suspension is characterized in that:
the suspension comprises a stabilizer solution and a donepezil nanocrystal suspended in the stabilizer solution;
the particle size range of the desonide nanocrystal is 100-1000nm, and the potential is-10 mv to 50mv;
the stabilizer solution is an aqueous solution of sodium dodecyl sulfate, and the mass fraction (g/g) of the sodium dodecyl sulfate is 10-20%.
2. The donepezil nanocrystal suspension of claim 1, wherein: the light scattering average particle size of the donepezil nanocrystal is 354.7nm, the PDI of the particle size distribution is 0.204, and the average potential is-26.9 mv.
3. The method of preparing a donepezil nanocrystal suspension according to claim 1 or 2, characterized in that: the method comprises the following steps of mixing aqueous solution of the desonide and the sodium dodecyl sulfate according to a ratio of 1:20 (g/ml) and grinding, and obtaining suspension, namely the suspension of the desonide nanocrystal after grinding.
4. The method of preparing a donepezil nanocrystal suspension of claim 3, wherein: the diniconide is pre-crushed to a particle size D90 of 5-10 mu m before being ground.
5. The method of preparing a donepezil nanocrystal suspension of claim 3, wherein: the grinding adopts a medium grinding method, the grinding equipment is a ball mill, and the grinding medium is zirconia beads.
6. The method of preparing a donepezil nanocrystal suspension of claim 5, wherein: the particle size of the zirconia beads is 0.4mm, and the ratio of the zirconia beads to the aqueous solution of sodium dodecyl sulfate is 1:5 (g/ml), and the milling parameters were 2000rpm,12h.
7. Use of the donepezil nanocrystal suspension of claim 1 or 2 in a topical formulation of donepezil.
8. Use of the donepezil nanocrystal suspension of claim 7 in a topical formulation of donepezil, characterized in that: the external preparation comprises cream, gel, ointment, and lotion.
9. The use of the donepezil nanocrystal suspension of claim 8 in a topical formulation of donepezil, wherein: the cream is prepared from a donepezil nanocrystal suspension, an oil phase, a water phase and a surfactant;
the oily matrix of the oil phase is one or more selected from light liquid paraffin, cetostearyl alcohol, white vaseline and beeswax;
the surfactant is a polyoxyethylene ether emulsifier, and the polyoxyethylene ether emulsifier is one or more selected from castor oil polyoxyethylene ether, nonylphenol polyoxyethylene ether, octylphenol polyoxyethylene ether, oleyl alcohol polyoxyethylene ether, fatty alcohol polyoxyethylene ether and methyl stearate polyoxyethylene ether.
10. The use of the donepezil nanocrystal suspension of claim 8 in a topical formulation of donepezil, wherein: the gel is prepared from a donepezil nanocrystal suspension, a thickening agent, a cellulose derivative, chitosan, polyvinylpyrrolidone and polyvinyl alcohol;
the thickening agent is carbomer, and the carbomer is selected from one or more of carbomer 940, carbomer 941, carbomer 934, carbomer 1342, carbomer 980, carbomer ETD 2020, carbomer SF-1 and carbomer Ultrez;
the cellulose derivative is selected from one or more of hydroxypropyl cellulose, hydroxypropyl methylcellulose and carboxymethyl cellulose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310004044.0A CN115844821A (en) | 2023-01-03 | 2023-01-03 | Desonide nanocrystal suspension, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310004044.0A CN115844821A (en) | 2023-01-03 | 2023-01-03 | Desonide nanocrystal suspension, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115844821A true CN115844821A (en) | 2023-03-28 |
Family
ID=85656771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310004044.0A Pending CN115844821A (en) | 2023-01-03 | 2023-01-03 | Desonide nanocrystal suspension, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115844821A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| AU2762700A (en) * | 1994-11-11 | 2000-06-15 | Medac Gesellschaft Fur Klinische Spezialpraparate Mbh | Pharmaceutical nanosuspensions for medicament administration as systems of increased saturation solubility and rate of solution |
| US20070065374A1 (en) * | 2005-03-16 | 2007-03-22 | Elan Pharma International Limited | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
| CN101180038A (en) * | 2005-03-23 | 2008-05-14 | 伊兰制药国际有限公司 | Nanoparticulate corticosteroid and antihistamine formulations |
| US20100255102A1 (en) * | 2003-05-22 | 2010-10-07 | Elan Pharma International Limited | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
-
2023
- 2023-01-03 CN CN202310004044.0A patent/CN115844821A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| AU2762700A (en) * | 1994-11-11 | 2000-06-15 | Medac Gesellschaft Fur Klinische Spezialpraparate Mbh | Pharmaceutical nanosuspensions for medicament administration as systems of increased saturation solubility and rate of solution |
| US20100255102A1 (en) * | 2003-05-22 | 2010-10-07 | Elan Pharma International Limited | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
| US20070065374A1 (en) * | 2005-03-16 | 2007-03-22 | Elan Pharma International Limited | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
| CN101180038A (en) * | 2005-03-23 | 2008-05-14 | 伊兰制药国际有限公司 | Nanoparticulate corticosteroid and antihistamine formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104887626A (en) | Preparation method of nano suspension | |
| TWI645852B (en) | Bioadhesive compositions for intranasal administration of granisetron | |
| Wei et al. | Hyaluronic acid based nanocrystals hydrogels for enhanced topical delivery of drug: A case study | |
| US20100105750A1 (en) | Stable metronidazole gel formulations | |
| CN103505420A (en) | Liquid crystal nano-preparations as well as preparation method thereof | |
| WO2020034989A1 (en) | Injectable pharmaceutical composition and preparation method therefor | |
| KR101397114B1 (en) | Composition for external application to the scar treatment | |
| JP5784619B2 (en) | Method for wetting powders containing benzoyl peroxide | |
| Hajare et al. | Lipid nanoparticles: A modern formulation approach in topical drug delivery systems | |
| CN115844821A (en) | Desonide nanocrystal suspension, preparation method and application thereof | |
| CN100502850C (en) | Medicinal composition of total capsicine compounds and beta-cyclodextrin or derivative of beta-cyclodextrin | |
| CN103263385B (en) | A kind of celecoxib long-acing nano injection and preparation method thereof | |
| PT2204174E (en) | Metronidazole solubilisation process with niacinamide and two glycols, and the resulting solution | |
| JP5753089B2 (en) | Method for obtaining a stable dispersion of benzoyl peroxide | |
| EP2317989A2 (en) | Microparticles | |
| CN113577013B (en) | Transdermal drug delivery composition containing dapsone compounds and preparation method thereof | |
| CN113577022A (en) | Dapsone compound suspension and preparation method and application thereof | |
| KR20130031479A (en) | Method for preparing nanoparticles | |
| JP4959991B2 (en) | Suspension pharmaceutical composition containing tranilast or a pharmacologically acceptable salt thereof | |
| CN113797166B (en) | Oxybutynin nanosuspension, composition containing oxybutynin nanosuspension and preparation method of oxybutynin nanosuspension | |
| JP4590224B2 (en) | Suspended pharmaceutical composition containing tranilast or a pharmacologically acceptable salt | |
| US20110092562A1 (en) | Method for wetting a powder containing benzoyl peroxide | |
| Singh et al. | New Insights into Pharmaceutical Nanocrystals for the Improved Topical Delivery of Therapeutics in Various Skin Disorders | |
| Shukurov | OBTAINING OF DRUG FILMS FOR THE TREATMENT OF VIRAL DISEASES OF THE ORAL CAVITY | |
| CN113616594A (en) | Preparation of progesterone nanocrystalline injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |